Skip to content
National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
Division of Cancer Prevention logo
Home Site Map Contact DCP
Programs & Resources

Prostate and Urologic Cancer Research Group

Programs and Projects

Skin Cancer Clinical Trials - University of California, Irvine Medical Center (Multicenter Sites)

Agent: Lovastatin
Contact: Kenneth Linden, MD
DCP Program Director: Joe Tangrea, MPH, PhD

The purpose of this study is to evaluate the potential of Lovastatin as a chemopreventive agent for skin cancer. Subjects with a history of melanoma, with at least 2 atypical moles, and who are not eligible for or have declined adjuvant treatments, or have finished adjuvant treatments may be eligible to participate in this study. Those taking part in the study will receive lovastatin or placebo by mouth for 6 months. Participants will undergo biopsy of skin lesions before and after receiving study treatment. The study is being conducted at the University of California, Irvine Medical Center and several other study sites through the University of California, Irvine Clinical Trials Consortium. As of May 2007, sites are actively accruing participants to this trial.

[This is a phase 2 randomized double-blind placebo controlled multicenter trial of Lovastatin compared to placebo for the prevention of skin cancer. Patients with a history of melanoma and two atypical nevi matched for atypia or a history of melanoma and one large > 8mm diameter nevus plus one other atypical nevus will receive 6 months of study medication. Histologic diagnosis is not required for enrollment. Participants should have no evidence of distant metastasis.]